

## TRANSPARENCY NOTIFICATIONS

\*rectified version of 17 July 2015

**Liège (Belgium), 10 July 2015, 18h30 (Belgian time) – regulated information** – In accordance with article 14 of the Law of 2 May 2007 on the disclosure of large shareholdings, **Mithra Pharmaceuticals SA/NV** publishes the following information:

- Mr François Fornieri has announced that, at the time of the initial public offering of Mithra Pharmaceuticals SA/NV on 30 June 2015, he held 9,610,229 Mithra shares and 903,571 assimilated financial instruments (stock lending agreement), representing 34.42% of the total number of voting rights (30,542,992).
- Mr Marc Coucke has announced that, at the time of the initial public offering of Mithra Pharmaceuticals SA/NV on 30 June 2015, he held 5,133,124 Mithra shares, representing 16.81% of the total number of voting rights (30,542,992).
- Alychlo NV (a company controlled by Mr Marc Coucke) has announced that, at the time of the initial public offering of Mithra Pharmaceuticals SA/NV on 30 June 2015, it held 3,964,322 Mithra shares, representing 12.98% of the total number of voting rights (30,542,992).
- Meusinvest SA has announced that, at the time of the initial public offering of Mithra Pharmaceuticals SA/NV on 30 June 2015, he held a shareholding that it held \*5,008,766 Mithra shares, representing \*16.40% of the total number of voting rights (30,542,992).
- OGEO FUND OFP has announced that, at the time of the initial public offering of Mithra Pharmaceuticals SA/NV on 30 June 2015, he held a shareholding that it held 1,481,700 Mithra shares, representing 4.85% of the total number of voting rights (30,542,992).

The detailed transparency notifications are available on Mithra Pharmaceuticals SA/NV's [website](http://www.mithra.com/) (<http://www.mithra.com/>).

An updated overview of the Mithra Pharmaceuticals SA/NV large shareholdings will be included in the corporate governance charter of Mithra Pharmaceuticals SA/NV, which will be made available on its website.

## For more information, please contact:

### **Julie Dessart**

Head of Communications

+32 4 349 28 22

+32 475 86 41 75

[jdessart@mithra.com](mailto:jdessart@mithra.com)

### **Jean-Manuel Fontaine**

Public Relations

+32 4 349 28 22

+32 476 96 54 59

[jmfontaine@mithra.com](mailto:jmfontaine@mithra.com)

### **François Fornieri, CEO/ Steven Peters, CFO**

+32 4 349 28 22

[investorrelations@mithra.com](mailto:investorrelations@mithra.com)

## About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on women's health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and generic products in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: [www.mithra.com](http://www.mithra.com)

## Important information

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*